Pharming Group NV (PHAR) is now in the Overvalued zone, suggesting that its current forward PS ratio of 3.03 is considered Overvalued compared with the five-year average of -55.83. The fair price of Pharming Group NV (PHAR) is between -25.17 to -20.43 according to relative valuation method. Compared to the current price of 15.40 USD , Pharming Group NV By Overvalued By -175.4%.

Relative Value

Fair Zone

-25.17--20.43

Current Price：15.40

-175.4%

Overvalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Pharming Group NV (PHAR) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Pharming Group NV (PHAR) has a current Price-to-Book (P/B) ratio of 32.53. Compared to its 3-year average P/B ratio of 13.02, the current P/B ratio is approximately 149.88% higher. Relative to its 5-year average P/B ratio of 9.00, the current P/B ratio is about 261.34% higher. Pharming Group NV (PHAR) has a Forward Free Cash Flow (FCF) yield of approximately 4.49%. Compared to its 3-year average FCF yield of -0.03%, the current FCF yield is approximately -16371.25% lower. Relative to its 5-year average FCF yield of 2.14%, the current FCF yield is about 110.25% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for PHAR competitors is -28.95, providing a benchmark for relative valuation. Pharming Group NV Corp (PHAR.O) exhibits a P/S ratio of 3.03, which is -110.46% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of PHAR increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of PHAR in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is PHAR currently overvalued or undervalued?

What is Pharming Group NV (PHAR) fair value?

PHAR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Pharming Group NV (PHAR) is between -25.17 to -20.43 according to relative valuation method.

How does PHAR's valuation metrics compare to the industry average?

The average P/S ratio for PHAR's competitors is -28.95, providing a benchmark for relative valuation. Pharming Group NV Corp (PHAR) exhibits a P/S ratio of 3.03, which is -110.46% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for Pharming Group NV (PHAR) as of Mar 04 2026?

As of Mar 04 2026, Pharming Group NV (PHAR) has a P/B ratio of 32.53. This indicates that the market values PHAR at 32.53 times its book value.

What is the current FCF Yield for Pharming Group NV (PHAR) as of Mar 04 2026?

As of Mar 04 2026, Pharming Group NV (PHAR) has a FCF Yield of 4.49%. This means that for every dollar of Pharming Group NV's market capitalization, the company generates 4.49 cents in free cash flow.

What is the current Forward P/E ratio for Pharming Group NV (PHAR) as of Mar 04 2026?

As of Mar 04 2026, Pharming Group NV (PHAR) has a Forward P/E ratio of 337.40. This means the market is willing to pay $337.40 for every dollar of Pharming Group NV's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Pharming Group NV (PHAR) as of Mar 04 2026?

As of Mar 04 2026, Pharming Group NV (PHAR) has a Forward P/S ratio of 3.03. This means the market is valuing PHAR at $3.03 for every dollar of expected revenue over the next 12 months.

PHAR Valuation